Pfiz­er joins Sanofi on the C. dif­fi­cile fail­ure train af­ter its vac­cine flopped a PhI­II study

Big Phar­ma has been try­ing to come up with a vac­cine for C. dif­fi­cile in­fec­tion for years, but one more pro­gram joined the heap of re­cent fail­ures.

Pfiz­er re­port­ed that a Phase III study of its ex­per­i­men­tal shot did not meet its pri­ma­ry end­point for pre­vent­ing the in­fec­tion, the com­pa­ny said ear­ly Tues­day. Pfiz­er’s plans for the can­di­date, dubbed PF-06425090, are not yet clear, but the com­pa­ny hint­ed at a strat­e­gy cen­tered around a sig­nal shown in some sec­ondary end­points.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.